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Palladium-Mediated 11C-Carbonylations Using Aryl Halides and 
Cyanamide 
P. Nordeman,a S. Y. Chow,b A. F. Odell,c G. Antoni,a and L. R. Odellb* 
A robust and high-yielding radiochemical synthesis of 11C-N-cyanobenzamides using a palladium-mediated 
aminocarbonylation with 11C-CO ? ĂƌǇů ŚĂůŝĚĞƐ ĂŶĚ ĐǇĂŶĂŵŝĚĞ ŝƐ ĚĞƐĐƌŝďĞĚ ? dŚĞ ďŝĚĞŶƚĂƚĞ ůŝŐĂŶĚ  ? ? ? ‘-
bis(diphenylphosphino)ferrocene provided 11C-N-cyanobenzamides from aryl- iodides, bromides, triflates and even 
chlorides in 28-79% radiochemical yield after semi-preparative HPLC. To futher highlight the utility of this method, novel 
11C-N-cyanobenzamide analogs of flufenamic acid, meflanamic acid, dazoxiben and tamibarotene were synthesized in 34-
71% radiochemical yields. 
Introduction 
Positron emission tomography (PET) is a powerful noninvasive 
modality for the visualization of biological functions, in real 
time, using a positron emitting nuclide incorporated into a 
bioactive molecule (tracer).1,2 PET is an important clinical 
diagnostic tool and has found extensive use in the monitoring 
of disease progression and treatment response in cancer 
patients.2-4 PET has also emerged as an enabling tool to study 
the underlying biological processes in many neurological 
disorders and in the development of drugs targeting the CNS.5 
One of the most important nuclides used in PET is the 
cyclotron-produced carbon-11 (11C) with a half-life of 20.4 
min.6 This is mainly due to the potential introduction of the 
carbon nuclide into various positions in a molecule of interest 
without disturbing its biological activity. 11C is typically 
produced in the form of 11C-carbon dioxide (11CO2) and can be 
readily transformed into a number of key building blocks 
including 11C-carbon monoxide (11CO).7,8 The synthetic 
versatility of 11CO is well-known and it can be utilized in 
various metal-mediated reactions yielding a host of different 
carbonyl and carboxylic acid derivatives including amides, 
acids, esters and ketones.9-13 
Despite these advances, there are a multitude of 
biologically important functional groups and scaffolds that 
cannot be prepared using existing 11CO technology. This 
highlights one of the major limitations of PET, namely the lack 
of generally applicable methods for the incorporation of the 
radionuclide into a target molecule. This has created a 
situation where tracer synthesis is dominated by a handful of 
synthetic methods (e.g. methylation) and potential tracers are 
invariably designed to conform within the narrow confines of 
existing chemistry, rather being naturally guided by target 
biology. To overcome these issues, there is an increasing 
demand for the development of new radiochemical methods 
that are suitable for the labelling of complex biologically active 
molecules. The use of 11C, however, poses a number of 
additional challenges as the short half-life of 11C demands the 
development of fast and efficient reactions. 
Bioisosteric replacement has played a vital role in drug 
discovery and development since the term was first coined in 
ƚŚĞ ? ? ? ? ?ƐďǇ,ĂƌƌŝƐ&ƌŝĞĚŵĂŶ ?14,15 The concept is based upon 
the assumption that atoms or functional groups with 
comparably shapes and/or physicochemical properties will 
interact similarly with a biological target and elicit analogous 
biological effects.15 Thus, bioisosteres have been employed to 
improve potency and selectivity, alter physical properties, 
modulate metabolism, increase permeability and adsorption 
and reduce the toxicity of a biologically active compound.16 
However, despite the widespread use of bioisosteres to 
optimize these properties in drug discovery and development, 
this strategy remains largely unexplored in the field of PET 
tracer development. 
The carboxylic acid is an important functional group 
capable of interacting with a biological target through both 
hydrogen bonding and electrostatic interactions. Carboxylic 
acids can also increase aqueous solubility and influence 
pharmacokinetics and are found in a wide range of drug and 
biologically active molecules. This has led to the development 
of several bioisosteres for this moiety.15-20 
N-Cyanobenzamides (Scheme 1) are an interesting, yet 
relatively unexplored, class of carbonyl derivatives.21,22 They 
have been employed as intermediates in the synthesis of 
diverse heterocyclic scaffolds and they have also found utility 
as carboxylic acid bioisosteres in a number of biologically 
active molecules.20,23,24 Recently, we reported the 
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carbonylative synthesis of this functional group, under 
palladium(0)catalysis, starting from an aryl halide, cyanamide 
and carbon monoxide using a bridged two compartment 
setup.25,26 Realizing that this provided an excellent starting 
point for the development of 11CO-carbonylation chemistry we 
sought to develop the first synthetic procedure for the 
preparation of 11C-labelled N-cyanobenzamides.6,27 This would 
make a valuable addition to the radiochemistry toolbox, 
opening up a new area of 11C-chemical space, that can be 
exploited in the design and synthesis of novel PET tracers. 
Herein, we describe a rapid, robust and high yielding method 
for the preparation of 11C-N-cyanobenzamides via a palladium 
mediated carbonylation using an aryl halide, cyanamide and 
11CO (Scheme 1). 
 
Scheme 1. Pd-mediated synthesis of 11C-N-cyanobenzamides and 11C-benzamides 
Results and discussion  
Method development 
We initiated our search for suitable reaction conditions using 
iodobenzene and cyanamide as model substrates, with 
bis(dibenzylidene-acetone)palladium(0) as the palladium 
source. THF has previously been successfully used as a solvent 
for 11C-carbonylations,28 however, the more polar DMF readily 
dissolved all components and was therefore chosen for further 
evaluation. The radiotrapping efficiency (RTE, defined here as 
the fraction of immobilized 11CO at the end of synthesis [EOS]) 
was determined by removal of non-reacted 11CO by flushing 
the crude reaction mixture with helium for 1 min. 
The ligand-free carbonylation resulted in a RTE of 85% and 
gave conversion of trapped 11CO to product (RCP) of 88% 
(Table 1, entry 1) as measured by radio-HPLC. We continued by 
evaluating the monodentate ligand triphenyphosphine, which 
gave the desired product in the same quantity (RTE 95%, RCP 
75%, entry 2). Analysis of the crude reaction mixture suggested 
the presence of a side-product, which was identified as 11C-
benzoic acid by co-elution using analytical radio-HPLC. The 
bidentate ligand 4,5-bis(diphenylphosphino)-9,9-
dimethylxanthene (Xantphos) has previously been successfully 
in both 11CO and CO carbonylations.9,29-31 In our setup 
complete consumption of 11CO (RTE >99%) was achieved with 
this ligand at 120 °C and 150 °C but with lower RCP (61% and 
72%, entry 3-4). Interestingly, no formation of acid was 
detected using this ligand. The lower RCP was due to the 
formation of a highly lipophilic impurity, possibly the 11CO-Pd-
Xantphos intermediate prior to nucleophilic attack by 
cyanamide.29 We continued our ligand screening by using the 
less strained oxydi-2,1-phenylene)bis(diphenylphosphine) 
(DPEphos), however full trapping of 11CO was not achieved in 
the range 90-150 °C and no improvement in RCP was observed 
(entry 5- ? ? ? dŽ ŽƵƌ ĚĞůŝŐŚƚ ? ƚŚĞ ďŝĚĞŶƚĂƚĞ ůŝŐĂŶĚ  ? ? ? ?-
bis(diphenylphosphino)ferrocene (dppf) gave complete 
trapping of 11CO (RTE >99%) and the desired product in high 
RCP (94±2%, entry 8). This may be attributed to the flexible 
ligand backbone, allowing it to stabilize the electronically and 
structurally disparate intermediates (i.e. Pd(0) and Pd(II)) 
formed during the reaction.32-34 When the temperature was 
increased to 150 °C, small amounts of unknown side-products 
were detected in the reaction mixture (entry 9). Using lower 
temperature gave lower RTE (84%) indicating that higher 
temperatures were essential for the effective conversion of 
iodobenzene to the corresponding 11C-N-cyanobenzamide 11C-
2a. 
 
 
 
 
 
Table 1. Optimization of Reaction Conditionsa 
n Ligand Temp (°C) RTE (%)b RCP (%)c 
1 - 120 85 88 
2 PPh3 120 95 75 
3 Xantphos 120 >99 61 
4 Xantphos 150 >99 72 
5 DPEPhos 90 85 88 
6 DPEPhos 120 76 79 
7 DPEPhos 150 82 86 
8 dppf 120 >99 94±2d 
9 dppf 150 >99 87 
10 dppf 90 84 86 
11e dppf 120 84 87 
12e dppf 140 96±2 93±3d 
13e dppf 150 93 90 
14f dppf 170 63 74 
15g dppf 120 89 88 
aReaction conditions: Ph-I (20 µmol), H2NCN (400 µmol), Pd(dba)2 (8 
µmol), Ligand (monodentate 20 µmol, bidentate 10 µmol), DMF (400 
µL), temp, 5 min. bThe fraction of immobilized 11CO after purging with 
N2. cDetermined by analytical radio-HPLC. dAverage of three 
experiments. ePh-Br was used. fPh-Cl was used. gPh-OTf was used. 
 
Encouraged by the promising result obtained with 
iodobenzene, the best conditions (entry 8) were used for the 
reaction of cyanamide with bromobenzene. This gave a RTE of 
84% and RCP of 87%. When the temperature was increased to 
140 °C, the product was formed in a high RCP of 89±3% with 
almost quantitative RTE (96±2%, Table 1, entry 12). Increasing 
the temperature to 150 °C again resulted in an erosion of the 
yield due to the formation of unknown side-products (entry 
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13). Next, we proceeded by evaluating the less reactive 
chlorobenzene in the carbonylative reaction. At 170 °C the RTE 
was 63% and the RCP 74% (entry 14). The pseudo-halide 
phenyl triflate was reacted under similar conditions as 
iodobenzene and was found to smoothly undergo 
carbonylation at 120 °C with RTE of 89% and RCP of 88% (entry 
15).  
With a suitable carbonylative protocol in hand, we 
continued by exploring the generality of the method using aryl 
iodides with different electronic properties (Table 2). Here the 
RTE and RCP for each reaction was determined as well as the 
isolated radiochemical yield (RCY) following semi-preparative 
HPLC. From iodobenzene and phenyl triflate 11C-N-cyano-
benzamide 11C-2a was isolated in 79% and 72% RCY, 
respectively. Substrates bearing electron withdrawing (EWG) 
and electron donating (EDG) groups in the 4-position 
performed well affording the desired products in moderate to 
high isolated radiochemical yield (11C-2b-f, 41-73%). A good 
yield was also obtained when the methoxy group was moved 
to the 3-position furnishing 64% RCY of 11C-2g. Notably, full 
chemoselectivity was achieved in the reaction with 1-chloro-4-
iodidobenzene and 57% of the 4-chloro substituted product 
11C-2e was obtained. Finally, the ortho-CF3 containing 
substrate (entry 9) gave a lower RCY (28%) of the 
corresponding 11C-N-cyanobenzamide 11C-2h presumably due 
to a combination of unfavorable steric and electronic effects. 
 
Table 2. Reaction Scope Using Aryl Iodidesa 
n Ar-X Prod. 11C-2n RTE (%)b RCY (%)c 
1 Ph a >99 79 
2 Phd a 89 72 
3 4-OMe-Ph b 95±3 73 
4 4-CN-Ph c 92±2 62 
5 4-C6H5-Ph d 94±3 68 
6 4-Cl-Ph e 85±3 57 
7 4-COH-Ph f 72 41 
8 3-OMe-Ph g 82 64 
9 2-CF3-Ph h 64 28 
aReaction conditions: Ar-I (20 µmol), H2NCN (400 µmol), Pd(dba)2 (8 µmol), dppf 
(10 µmol), DMF (400 µL), 120 °C, 5 min. Values with ± indicate the average of 
three experiments. bThe fraction of immobilized 11CO after purging with N2. cAfter 
semi-preparative HPLC (decay corrected from EOB). RCP of the isolated products 
were >95%. dPh-OTf. 
To further extend the utility of the reaction, the scope was 
expanded to include aryl- and heteroaromatic bromides (Table 
3). By using the protocol from entry 12 in Table 1 (i.e. 
increasing the temperature to 140 °C), 11C-N-cyanobenzamide 
11C-2a was synthesized in 72% RCY. Using chlorobenzene at 
170 °C furnished the same product in reduced 34% RCY (entry 
2). Both the electron rich (entry 3) and electron deficient  
 
                  
Table 3. Reaction Scope Using Aryl Bromidesa                                                                                   
 n Ar-X 
 
Temp Prod. 
11C-n 
RTE 
(%)b 
RCY 
(%)c 
1 Ph 140 2a 96±2 72 
2 Phd 170 2a 63 34 
3 4-OMe-Ph 140 2b 90 68 
4 4-CN-Ph 140 2c 91±4 67 
5 2-naphthalene 140 4a 94 51 
6 2-benzofuran 140 4b 88±1 48 
7 2-thiophene 140 4c 88±3 59 
8 3-thiophene 140 4d 84±1 64 
9 3-pyridine  140 4e 78 55 
aReaction conditions: Ar-Br (20 µmol), H2NCN (400 µmol), Pd(dba)2 (8 
µmol), dppf (10 µmol), DMF (400 µL), 140 or 170 °C, 5 min. Values with ± 
indicate the average of three experiments. bThe fraction of immobilized 
11CO after purging with N2. cAfter semi-preparative HPLC. RCP of the 
isolated products were >95%. dPh-Cl. 
substrates (entry 4) gave corresponding products 11C-2b and 
11C-2c in similar RCY wheras 2-bromonaphthalene 3e yielded 
labelled 11C-4a in 51% RCY.  
A number of electron-rich heterocycles were also 
effectively transformed into the corresponding 11C-N-
cyanamide products. 2-Bromobenzofurane afforded 11C-N-
cyanobenzofuran-2-carboxamide (11C-4b) in 48% RCY while 2- 
and 3-bromothiophene gave products 11C-4c and 11C-4d in 59% 
and 64% isolated RCY, respectively. Notably, 3-bromopyridine 
was transformed into 11C-N-cyanonicotinamide (11C-4e) in 55% 
RCY. 
 
Synthesis of 11C-cyanobenzamide analogs of various bioactive 
molecules 
To further exemplify our developed methodology, we 
explored the labeling with 11CO of N-cyanobenzamide analogs 
of a variety of bioactive molecules (Scheme 2). Firstly, we 
prepared the N-cyanobenzamide derivatives of flufenamic acid 
(11C-6) and mefenamic acid (11C-7), two nonsteroidal anti-
inflammatory and antipyretic drugs (NSAID) used to treat 
muscle and menstrual pain, respectively.35-37 This required 
access to the ortho-bromoaniline precursors 5a and 5b, which 
were synthesized via a palladium-catalyzed amination using 
5% tris(dibenzylidene-acetone)dipalladium(0) and 12% 
Xantphos as the ligand in 46% and 72% yield, respectively 
(Scheme 2A).38 Despite the potentially palladium-coordinating 
amino moiety in close vicinity to the bromide, the reactions 
performed well at 140 °C yielding 11C-6 in 54±2% RCY and 11C-7 
in 34±4% RCY. The precursor of the thromboxane synthase 
inhibitor dazoxiben was synthesized from 1-bromo-4-(2-
chloroeth-oxy)benzene (8) and imidazole in 78% yield (Scheme 
2B). Using the optimized conditions for aryl bromides, the 
radiolabelled 11C-10 was isolated using semi-preparative HPLC 
in 71±4%. 
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Scheme 2A. Precursor synthesis and radiolabeling of 11C-6 and 11C-7, analogs of flufenamic acid and mefanamic acid, respectively; 2B. Synthesis of 11C-N-cyanobenzamide analog of 
dazoxiben 11C-10. 2C. Radiosynthesis of 11C-N-cyanobenzamide 11C-12 and 11C-tamibarotene (11C-13) 
Finally, we synthesized compound 11 a precursor for the 
labelling of tamibarotene, a synthetic retinoic acid receptor 
agonist.39,40 Tamibarotene is approved in Japan for use against 
all-trans-retinoic acid refractive acute promyelocytic 
leukemia41 and is currently being investigated for the 
treatment of insulin resistence,42 vasculitis43 intracerebral 
hemorrhage44 ĂŶĚ ůǌŚŝĞŵĞƌ ?Ɛ ĚŝƐĞĂƐĞ ?45,46 11C-Tamibarotene 
(11C-13) was prepared from the iodo-precursor 11 via an 
alkoxycarbonylation using the conditions from Table 3 at 150 
°C using methanol as the nucleophile (Scheme 2C). Subsequent 
hydrolysis of the methyl ester intermediate using sodium 
hydroxide the afforded 11C-13 in 16% RCY and a specific 
activity of 205 GBq/µmol. Notably, our method gave a similar 
yield with a 5-fold improvement in specific activity compared 
to the oxidative alkoxylation procedure reported by Suzuki and 
co-workers (44 GBq/µmol and RCY 26±13%).47 Importantly, the 
corresponding 11C-N-cyanobenzamide analogue was 
synthesized using the optimized conditions for aryl iodides 
yielding 11C-12 in 55±8% RCY and a specific activity of 291 
GBq/µmol after semi-preparative-HPLC. The radiochemical 
purity in both syntheses was in excess of 99%. Thus, both the 
11C-labelled parent molecule and its corresponding 11C-
cyanobenzamide bioisostere were efficiently prepared from a 
common precursor, using similar reaction conditions, further 
highlighting the utility of the method developed herein. 
 
Conclusions 
In conclusion, a palladium mediated 11C-carbonylative 
methodology yielding 11C-N-cyanobenzamides from aryl 
halides has been described. The substrate scope was found to 
be excellent and electron rich as well as electron deficient aryl 
iodides and bromides all performed well. The method was also 
extended to include the carbonylation of challenging 
heteroaryl bromides, phenyl triflate and even chlorobenzene. 
Notably, good to high isolated radiochemical yields were 
obtained ranging from 28-79% after semi-preparative HPLC. 
Moreover, the developed method was exemplified by 
synthesizing novel 11C-N-cyanobenzamide analogs of the 
E^/ ‘Ɛ ĨůƵĨĞŶĂŵŝĐ ĂĐŝĚ ĂŶĚ ŵĞĨĞŶĂŵŝĐ ĂĐŝĚ ĂƐ ǁĞůl as 
dazoxiben and tamibarotene in 34-71% decay corrected RCY. 
This method allows rapid and robust access to new 11C-
chemical space and exploration of cyanobenzamide 
bioisosteres of the ubiquitous carboxylic acid group.  
Experimental 
General Chemical Information 
Chemicals were purchased from commercial suppliers and 
were used without further purification. NMR spectra were 
recorded on a Varian Mercury plus spectrometer (1H at 400 
MHz and 13C at 101 MHz) at ambient temperature. Chemical 
ƐŚŝĨƚƐ  ?ɷ ? ĂƌĞ ƌĞƉŽƌƚĞĚ ŝŶ ƉƉŵ ƌĞĨĞƌĞŶĐĞĚ ƚŽ ŵĞƚŚĂŶŽů ?
chloroform or DMSO. Thin-layer chromatography (TLC) was 
conducted on aluminum sheets precoated with silica gel 60 
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F254 (0.2 mm, Merck) and visualized by UV-light (254 nm). 
Flash column chromatography (FCC) was performed using 
silica gel 60 (40 W63 µm, Merck). Analytical UHPLC-MS was 
performed with an ion-trap mass spectrometer and UV-DAD 
detection using a C18 (50×3 mm) column using a gradient of 
10-90 (1.5 mL/min, 2 min) and MeCN (0.05% HCOOH) in H2O 
(0.05% HCOOH) as the eluent. 
11CO2 was created through the 14N(p,n)11C nuclear reaction 
at the Uppsala University Hospital by a Scandtronix MX17 
cyclotron and transferred to the hotlab where it was reduced 
over a bead of zinc (400 °C) and then used in the carbonylation 
reaction which was remotely controlled.48 Semi-preparative 
radio-HPLC was performed using a VWR LaPrep HPLC system 
(P110, P311) with a Beckman CoutlerTM UltrapshereTM ODS 
column (10×250mm) with a gradient of 10-90 % (6 mL/min, 10 
min) of MeCN in H2O. Analytical radio-HPLC was performed 
using a VWR LaChrom ELITE system (L-2130, L-2200, L-2400) 
with a Merck Chromolith Performance RP-18e column 
(4.6×100mm) and a gradient of 10-90 (method 1: 4 mL/min, 10 
min. Method 2: 4 mL/min, 5 min. Method 3: 4 mL/min, 7 min) 
MeCN in H2O. Both HPLC-systems were buffered with 0.09% 
TFA (for purification of 11C-6, 0.1% HCOOH was used), used 
254 nm UV-detection and were equipped with a Bioscan Flow-
Count PMT radioactivity detector. See supporting information 
for further information. 
Synthesis and characterization of precursors and references 
Compounds 2a-e, 4a and 4e are known and were synthesized 
according to reference 24. Compounds 2f, 2g, 4b, 4d, 6, 7, 10, 
12 were synthesized in a peptide coupling reaction from the 
corresponding carboxylic acid. The carboxylic acid (0.5 mmol), 
PyBOP (260 mg, 0.5 mmol), Et3N (436 µL, 2.5 mmol), 
cyanamide (32 mg, 0.75 mmol) were dissolved in 1,4-dioxane 
(2 mL) and the reaction was stirred for 12 hours at ambient 
temperature. The crude mixture was concentrated and 
purified by FCC (Acetone/MeOH [99:1] containing 2% Et3N). 
Compounds 2h and 4c were synthesized from the 
corresponding acid chloride. The acid chloride (0.5 mmol), 
cyanamide (32 mg, 0.75 mmol), Et3N (174 µL, 1 mmol) were 
dissolved in 1,4-dioxane (2 mL) and stirred at 50 °C for 12 
hours. The mixture was concentrated and purified by FCC 
(Acetone/MeOH [99:1] containing 2% Et3N). This yielded 40-
70% of the corresponding N-acyl cyanamides as the Et3N-salt. 
N-Cyano-4-formylbenzamide (2f). 1H NMR (400 MHz, 
DĞK ?ɷ ? ? ? ? ? ?Ɛ ? ?, ? ? ? ? ? ? ?Ě ?J = 8.3 Hz, 2H), 7.91 (d, J = 8.3 
Hz, 2H), 3.22 (q, J = 7.3 Hz, 6H), 1.31 (t, J = 7.3 Hz, 9H). 13C NMR 
 ? ? ? ? D,ǌ ? DĞK ? ɷ  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ? ? ? ? ?
122.6, 47.9, 9.2. HRMS calcd for C9H6N2O2 [M+H]+ m/z 
175.0508, found m/z 175.0509. 
N-Cyano-3-methoxybenzamide (2g). 1H NMR (400 MHz, 
DĞK ? ɷ  ? ? ? ?-7.52 (m, 2H), 7.30-7.26 (m, 1H), 7.04-7.01 (m, 
1H), 3.81 (s, 3H), 3.20 (q, J = 7.3 Hz, 6H), 1.30 (t, J = 7.3, 9H). 13C 
EDZ  ? ? ? ? D,ǌ ? DĞK ? ɷ  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?
118.4, 114.4, 55.7, 47.9, 9.2. HRMS calcd for C10H6N2O2 [M+H]+ 
m/z 177.0664, found m/z 177.0660. 
N-Cyano-2-(trifluoromethyl)benzamide (2h). 1H NMR (400 
D,ǌ ?DĞK ?ɷ ? ? ? ?-7.68 (m, 1H), 7.64-7.52 (m, 3H), 3.21 (q, J 
= 7.3 Hz, 6H), 1.30 (t, J = 7.3 Hz, 9H). 13C NMR (100 MHz, 
DĞK ? ɷ  ? ? ? ? ? ?  ? ? ? ? ?  ?Ě ?J = 2.3 Hz), 131.6 (q, JC-F = 1.1 Hz), 
128.8, 128.2, 126.5 (q, JC-F = 31.8 Hz), 125.8 (q, J = 5.1 Hz), 
124.0 (q, J = 272.9 Hz), 119.4, 46.5, 7.8. HRMS calcd for 
C9H5F3N2O [M+H]+ m/z 215.0432, found m/z 215.0429. 
N-Cyanobenzofuran-2-carboxamide (4b). 1H NMR (400 
D,ǌ ?DĞK ?ɷ ? ? ? ? ?Ě ?J = 7.8 Hz, 1H), 7.54 (dd, J = 8.4, 0.8 Hz, 
1H), 7.43-7.36 (m, 2H), 7.29-7.24 (m, 1H), 3.20 (q, J = 7.3 Hz, 
6H), 1.29 (t, J = 7.3 Hz, 9H).13 EDZ ɷ  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?
129.1, 127.6, 124.5, 123.4, 121.3, 112.7, 111.2, 47.9, 9.2. 
HRMS calcd for C10H6N2O2 [M+H]+ m/z 187.0508, found m/z 
187.0509. 
N-Cyanothiophene-2-carboxamide (4c). 1H NMR (400 
D,ǌ ?DĞK ?ɷ ? ? ? ?-7.61 (m, 1H), 7.53-7.50 (m, 1H), 7.15-6.91 
(m, 1H), 3.20 (q, J = 7.3 Hz, 6H), 1.30 (t, J = 7.3 Hz, 9H). 13C NMR 
 ? ? ? ? D,ǌ ? DĞK ? ɷ  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ? ? ? ? ?
47.9, 9.2. HRMS calcd for C6H4N2OS [M+H]+ m/z 153.0123, 
found m/z 153.0129. 
N-Cyanonicotinamide (4e). 1, EDZ  ? ? ? ? D,ǌ ? DĞK ? ɷ
9.14-9.07 (m, 1H), 8.62 (dd, J = 5.1, 1.7 Hz, 1H), 8.41 (ddd, J = 
8.0, 2.2, 1.7 Hz, 1H), 7.51 (ddd, J = 8.0, 5.1, 0.9 Hz, 1H), 3.22 (q, 
J = 7.3 Hz, 6H), 1.32 (t, J = 7.3 Hz, 9H). 13C NMR (100 MHz, 
DĞK ?ɷ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
9.2. HRMS calcd for C7H5N3O [M+H]+ m/z 148.0511, found m/z 
148.0514. 
2-Bromo-N-(3-(trifluoromethyl)phenyl)aniline (5a). 3-
(trifluoromethyl)aniline (80 mg, 0.5 mmol), 1-bromo-2-
iodobenzene (141 mg, 0.5 mmol), tris(dibenzylidene-
acetone)dipalladium(0) (23 mg, 5 mol%), 4,5-bis(di-
phenylphosphino)-9,9-dimethylxanthene (35 mg, 12 mol%), 
cesium carbonate (488 mg, 1.5 mmol) was added to DMF (5 
mL), capped and stirred at 60 °C for 12 hours. After cooling, 
the mixture was filtered, concentrated and purified by FCC 
(pentane:EtOAc [7:1] yielding 73 mg (46%) of 5. 1,EDZɷ ? ? ? ?
(ddd, J = 8.0, 1.3, 0.5 Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.32-7.24 
(m, 2H), 7.24-7.18 (m, 2H), 7.14-7.10 (m, 1H), 6.93 (ddd, J = 
8.0, 6.4, 2.5 Hz, 1H).13EDZɷ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?Ƌ ?JC-
F = 31.8 Hz), 131.0 , 129.4, 125.7 (d, JC-F = 271.4 Hz), 124.9, 
122.1, 121.4, 117.6 (q, JC-F = 4.0 Hz), 117.1, 114.5(q, JC-F = 4.0 
Hz). HRMS calcd for C13H9NBrF3 [M+H]+ m/z 315.9949, found 
m/z 315.9944. 
N-(2-bromophenyl)-2,3-dimethylaniline (5b). Synthesized 
as per 5a from 2,3-dimethylaniline. 1H NMR (400 MHz, CDCl3 ?ɷ
7.65 (dd, J = 8.0, 1.5 Hz, 1H), 7.41 (s, 1H), 7.28-7.21 (m, 3H), 
7.17-7.15 (m, 1H), 6.87 (dd, J = 8.4, 1.5 Hz, 1H), 6.81 (ddd, J = 
8.0, 7.2, 1.5 Hz, 1H), 2.49 (s, 3H), 2.32 (s, 3H). 13C NMR (101 
MHz, Chloroform-d ?ɷ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
128.15, 126.39, 126.12, 121.72, 119.56, 110.82, 20.67, 13.89. 
HRMS: m/z = 276.0395 [M + H]+, calculated for C14H15NBr: 
276.0388 
N-Cyano-2-((3-(trifluoromethyl)phenyl)amino)benzamide 
(6). 1H NMR (400 MHz, DMSO-d6) ɷ  ? ? ? ?  ?Ě ?J = 7.9 Hz, 1H), 
7.48-7.37 (m, 3H), 7.29 (d, J = 3.1 Hz, 2H), 7.19 (d, J = 7.7 Hz, 
1H), 6.86-6.77 (m, 1H), 3.18 (q, J = 7.3 Hz, 6H), 1.28 (t, J = 7.3 
Hz, 9H). 13C NMR (101 MHz, DMSO-d6) ɷ180.6, 145.6, 144.6, 
132.9, 132.7, 132.6 (q, 2JCF = 32.0 Hz), 131.2, 125.6 (q, 1JCF = 
271.4 Hz), 123.5 (q, 4JCF = 1.5 Hz), 123.0, 122.4, 119.8, 118.6 (q, 
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3JCF = 4.0 Hz), 116.24 (d, 3JCF = 4.0 Hz), 116.18, 47.9, 9.2. HRMS 
calcd for C15H10F3N3O [M+H]+ m/z 306.0854, found m/z 
306.0859. 
N-Cyano-2-((2,3-dimethylphenyl)amino)benzamide (7). 1H 
NMR (400 MHz, DMSO-d6) ɷ 8.01 (dd, J = 7.8, 1.6 Hz, 1H), 7.49 
 W 7.35 (m, 3H), 7.28  W 7.18 (m, 2H), 6.26 (dd, J = 8.4, 0.9 Hz, 
1H), 2.36 (s, 3H), 1.90 (s, 3H). 13C NMR (101 MHz, DMSO-d6) ɷ 
167.2, 155.2, 141.4, 139.6, 135.3, 133.8, 133.0, 131.6, 127.9, 
126.9, 126.6, 123.3, 117.9, 114.6, 20.0, 13.3. HRMS calcd for 
C16H16N3O [M + H]+, 266.1293, found 266.1301. 
1-(2-(4-Bromophenoxy)ethyl)-1H-imidazole (9). 1H NMR 
 ? ? ? ?D,ǌ ?DĞK ?ɷ ? ? ? ? ?ƚ ?J = 1.1 Hz, 1H), 7.41 W7.33 (m, 2H), 
7.21 (t, J = 1.3 Hz, 1H), 6.97 (t, J = 1.2 Hz, 1H), 6.86 W6.81 (m, 
2H), 4.40 (dd, J = 5.5, 4.5 Hz, 2H), 4.23 (dd, J = 5.5, 4.5 Hz, 2H). 
13EDZ ? ? ? ?D,ǌ ?DĞK ?ɷ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?  
117.6, 114.3, 68.8, 47.5. ESI-HRMS calcd for C11H12BrN2O 
[M+H]+ m/z 267.0133, found m/z 267.0133. 
4-(2-(1H-Imidazol-1-yl)ethoxy)-N-cyanobenzamide (10). 1H 
EDZ ? ? ? ?D,ǌ ?DĞK ?ɷ ? ? ? ? ?Ě ?J = 9.0 Hz, 2H), 7.77 (s, 1H), 
7.25 (s, 1H), 6.99 (s, 1H), 6.89 (d, J = 9.0 Hz, 1H), 4.47  W 4.39 
(m, 2H), 4.34  W 4.27 (m, 2H), 3.20 (q, J = 7.3 Hz, 6H), 1.30 (t, J = 
7.3 Hz, 12H). 13EDZ ? ? ? ?D,ǌ ?DĞK ?ɷ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
131.6, 131.1, 128.7, 123.3, 121.2, 114.7, 68.5, 47.9, 29.9, 9.3. 
ESI-HRMS calcd for C13H13N4O2 [M+H]+ m/z 257.1039, found 
m/z 257.1037. 
4-Iodo-N-(5,5,8,8-tetramethyl-5,6,7,8-
tetrahydronaphthalen-2-yl)benzamide (11). The compound 
was synthesized according to reference 49 using 4-iodobenzoic 
acid. 1,EDZ ? ? ? ?D,ǌ ?D^K ?ɷ ? ? ? ? ? ?Ɛ ? ?, ? ? ? ? ? ? ?Ě ?J = 8.2 
Hz, 2H), 7.74 (d, J = 8.2 Hz, 2H), 7.65 (d, J = 1.8 Hz, 2H), 7.55 (d, 
J = 8.7 Hz, 1H), 7.27 (d, J = 8.6 Hz, 1H), 1.64 (s, 4H), 1.23 (d, J = 
4.7 Hz, 12H). 13EDZ ? ? ? ?D,ǌ ?D^K ?ɷ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
137.2, 136.4, 134.4, 129.5, 126.4, 118.3, 118.1, 99.1, 34.6, 
34.6, 34.0, 33.6, 31.6, 31.6. ESI-HRMS calcd for C21H25INO 
[M+H]+ m/z 434.0981, found m/z 434.0982. 
N1-Cyano-N4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-yl)terephthalamide (12). 1H NMR (400 MHz, 
D^K ?ɷ ? ? ? ? ? ?Ɛ ? ?, ? ? ? ? ? ? ?Ě ?J = 8.6 Hz, 2H), 8.03 (d, J = 8.6 
Hz, 2H), 7.73  W 7.64 (m, 1H), 7.64  W 7.53 (m, 1H), 7.29 (d, J = 8.6 
Hz, 1H), 1.65 (s, 6H), 1.24 (d, J = 5.2 Hz, 12H). 13C NMR (101 
D,ǌ ?D^K ?ɷ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
128.3, 128.0, 126.5, 118.3, 118.1, 109.6, 34.6, 34.6, 34.0, 33.6, 
31.7, 31.6. ESI-HRMS calcd for C23H26N3O2 [M+H]+ m/z 
376.2025, found m/z 376.2037. 
4-((5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-
yl)carbamoyl)benzoic acid (13). 1, EDZ  ? ? ? ? D,ǌ ? D^K ? ɷ
10.24 (s, 1H), 8.13  W 7.93 (m, 4H), 7.67 (s, 1H), 7.58 (d, J = 10.9 
Hz, 1H), 7.29 (d, J = 8.6 Hz, 1H), 1.64 (s, 4H), 1.24 (d, J = 5.0 Hz, 
12H). 13EDZ ? ? ? ?D,ǌ ?D^K ?ɷ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
139.2, 136.8, 133.8, 129.7, 128.2, 126.9, 118.8, 118.6, 35.0, 
34.4, 34.0, 32.1, 32.1. ESI-HRMS calcd for C22H26NO3 [M+H]+ 
m/z 352.1913, found m/z 352.1913. 
Radiochemistry 
The aryl halide (20 µmol) and cyanamide (16.8 mg, 400 µmol) 
were added to an oven dried 2 mL vial, capped and flushed for 
2 min with argon. To a second oven dried 2 mL vial was added 
bis(dibenzylideneacetone)-palladium(0) (2.3 mg, 8 µmol) and 
 ? ? ? ‘-bis(diphenyl-phosphino)ferrocene (4.8 mg, 10 µmol) 
which was then capped and flushed with argon for 2 min 
before dry DMF (400 µL) was added. After a second flush with 
argon (2 min) the DMF/Pd(dba)2/dppf solution was heated at 
90 °C for 1 min, creating a homogenous solution. The mixture 
was added to the first vial and subsequently added to the 
injection loop (200 µL capacity) of the 11C-carbon monoxide 
system.47 After the reaction was finished, the radioactivity was 
measured. After flushing with nitrogen for 1 min, the activity 
was measured again yielding the RTE. An aliquot was taken for 
the determination of RCP. The crude mixture was diluted with 
50% aqueous MeCN (total volume 500 µL) and purified by 
semi-preparative radio-HPLC. After collecting the product, RCP 
was determined for the pure product. The identity was 
determined by co-elution of the corresponding non-
isotopically labeled N-cyanobenzamide. For the molar activity 
of 11C-12 and 11C-13, a calibration curve with five points using 
the corresponding reference. The total mass and the 
concentration of the purified product was then determined. 
The amount of activity was calculated back to the end of 
synthesis to get comparable data, expressed in GBq/µmol. The 
molar activity was determined to be 291 GBq/µmol for 11C-12 
and 205 GBq/µmol for 11C-13. 
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